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Until recently, it was accepted that only a few specific
types of cancer were associated with the immune defi-
ciency associated with HIV infection. Although it is
known that a number of other cancers occur at increased
rates, most studies have concluded that these cancers
occur at increased rates because of lifestyle risk factors for
cancer in people with HIV, rather than a direct effect of
immune deficiency. In the past year, this paradigm has
been challenged by the finding that solid organ transplant
recipients have a profile of increased cancer incidence that
is strikingly similar to people with HIV. As these two pop-
ulations share little in terms of lifestyle risks for cancer, it
appears that immune deficiency must underlie these
increased risks. Most of cancers occurring at increased
incidence are those known or suspected to be related to
oncogenic infective agents including Epstein-Barr virus
(non-Hodgkin lymphoma (NHL), Hodgkin lymphoma),
human herpesvirus 8 (Kaposi's sarcoma, KS), human pap-
illomavirus (anogenital and head and neck cancers), hep-
atitis B and C virus (liver cancer), and Helicobacter pylori
(stomach cancer). Most epithelial cancers common in the
general population (e.g. breast, prostate and ovarian) do
not occur at increased risk. Although it is now clear that
immune deficiency causes increased incidence of many
cancers, there remains uncertainty about the level of
immune function required to prevent increased rates of
cancer. In transplant recipients, rates of many cancers rap-
idly return towards normal on cessation of iatrogenic
immune suppression. In people with HIV, rates of NHL
and KS have declined markedly since the widespread use
of combination antiretroviral therapy, but rates remain
raised above population levels. For Hodgkin lymphoma,
its incidence is highest when immune deficiency is mod-
erate rather than profound. For other cancers, there are
few data on rates by level of immune deficiency. Describ-
ing cancer rates by level of immune function is an impor-
tant research priority among people with HIV. If cancer
incidence is raised even in the modestly immune defi-
cient, cancer risk may become an important consideration
in deciding when to start HIV therapy, and in the setting
of goals for optimal immune recovery.
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